The discovery of the Philadelphia chromosome has revolutionized the treatment of CML. Targeted therapies such as tyrosine kinase inhibitors (TKIs) specifically inhibit the activity of the BCR-ABL1 protein, leading to significant improvements in patient outcomes. Epidemiological data show that patients receiving TKIs have a much better prognosis compared to those receiving traditional chemotherapy.
